Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

<< Previous

Bullboard Posts

Next >>

Post by Noteableon Nov 24, 2022 10:43am

256 Views

Post# 35125051

The BUZZ on ONCY's Pancreatic trial on Mayo Connect

Pancreatic Cancer Trials that look promising

Posted by askretka @askretka, Aug 25 4:02am

In simple words, we gave a combination of drugs ( pelareorep+ atezolizumab and chemo) to mPDAC patients, which is one of the worst cancers, and 3/3 “safety run-in” patients showed about 50% reduction in their tumor sizes in just 4 months!This is great